Alcon makes a move for WaveLight

August 23, 2007

Article

Alcon has announced its intention to acquire WaveLight AG by means of a friendly takeover, with both parties entering into a business combination agreement.

Alcon has announced its intention to acquire WaveLight AG by means of a friendly takeover, with both parties entering into a business combination agreement.

Alcon will reportedly offer 10 per share in cash for all issued WaveLight shares. WaveLight's Executive Committee reportedly supports the transaction and will recommend to the shareholders that it be accepted, subject to a review of the published tender offer document.

The deal will be contingent on the fulfilment of various terms and conditions, including a minimum acceptance threshold of 75% of WaveLight's issued shares and approval by the relevant merger control authorities.

Recent Videos

Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT

Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium

I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.

Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times

Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting

Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA

Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting

Related Content

A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

A woman with myopia holds a pair of glasses at a distance and looks through the vision-correcting lens. Paediatric myopia control concept. Image credit: ©Chanintorn.v – stock.adobe.com

French OPHTAMYOP study reveals trends in myopia control

Dominique Bremond-Gignac, MD, PhD, FEBO

How studies into myopia management can increase access to vision care

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

New study investigates ocular involvement in multiple myeloma

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

Related Content

A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

A woman with myopia holds a pair of glasses at a distance and looks through the vision-correcting lens. Paediatric myopia control concept. Image credit: ©Chanintorn.v – stock.adobe.com

French OPHTAMYOP study reveals trends in myopia control

Dominique Bremond-Gignac, MD, PhD, FEBO

How studies into myopia management can increase access to vision care

An image of the European Medicines Agency (EMA) headquarters to accompany a CHMP opinion. Image credit: ©Lubo Ivanko – stock.adobe.com

EMA grants positive CHMP opinion for low-dose atropine SYD-101 (Ryjunea, Sydnexis)

A pivotal phase 3 clinical trial found that SYD-101 met its 3-year primary endpoint for slowing paediatric myopia progression

A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

New study investigates ocular involvement in multiple myeloma

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

Editorial Board

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.